Fosun Pharma moves forward with Henlius Biotech merger and privatization

Shanghai Fosun Pharmaceutical (SSE:600196) announced an update on its plan to merge and privatize its subsidiary, Shanghai Henlius Biotech. Shareholders will vote on the proposed transaction at meetings scheduled for January 22, 2025. The plan involves Fosun's subsidiary, Shanghai Fosun New Drug Research, acquiring all outstanding Henlius shares (H-shares and unlisted shares) using a combination of cash and/or share exchange. Upon completion, Henlius will be delisted and cease to exist as a separate legal entity, with Fosun New Drug assuming all assets, liabilities, and operations. While all pre-conditions for the merger agreement, including regulatory approvals, have been met, the transaction remains subject to shareholder and Hong Kong Stock Exchange approval. The company urges investors to exercise caution given the remaining uncertainties.